96
Ethics
Work on human beings that is submitted to IJAA should comply with the
principles laid down in the Declaration of Helsinki; Recommendations guiding
physicians in biomedical research involving human subjects. Adopted by the 18th
World Medical Assembly, Helsinki, Finland, June 1964, amended by the 29th
World Medical Assembly, Tokyo, Japan, October 1975, the 35th World Medical
Assembly, Venice, Italy, October 1983, and the 41st World Medical Assembly,
Hong Kong, September 1989. The manuscript should contain a statement that the
work has been approved by the appropriate ethical committees related to the
institution(s) in which it was performed and that subjects gave informed consent
to the work (see declarations section above). Studies involving experiments with
animals must state that their care was in accordance with institution guidelines.
Patients' and volunteers' names, initials, and hospital numbers should not be used.
Competing interests
See the declarations section above. All authors must disclose any financial and
personal relationships with other people or organisations that could
inappropriately influence (bias) their work. Examples of potential conflicts of
interest include employment, consultancies, stock ownership, honoraria, paid
expert testimony, patent applications/registrations, and grants or other funding.
Role of the funding source
See the declarations section. All sources of funding should be declared. Authors
should declare the role of study sponsors, if any, in the study design, in the
collection, analysis and interpretation of data; in the writing of the manuscript;
and in the decision to submit the manuscript for publication. If the study sponsors
had no such involvement, the authors should so state.
Randomised controlled trials
All randomised controlled trials submitted for publication in IJAA should include
a completed Consolidated Standards of Reporting Trials (CONSORT) flow chart.
Please refer to the CONSORT statement website at
http://www.consort-
statement.org for more information. IJAA has adopted the proposal from the
International Committee of Medical Journal Editors (ICMJE) which require, as a
condition of consideration for publication of clinical trials, registration in a public
trials registry. Trials must register at or before the onset of patient enrolment. The
clinical trial registration number should be included at the end of the abstract of
the article. For this purpose, a clinical trial is defined as any research project that
prospectively assigns human subjects to intervention or comparison groups to
study the cause-and-effect relationship between a medical intervention and a
health outcome. Studies designed for other purposes, such as to study
pharmacokinetics or major toxicity (e.g. phase I trials) would be exempt. Further
information can be found at www.icmje.org.revisions received later than 3
months after this request will be treated as new submissions.
Authors in Japan please note: If you would like information about how to have
the English of your paper checked, corrected and improved (before
submission),please contact our Tokyo office who will inform you of the services
provided by language correctors: Elsevier Japan, 9-15 Higashi-Azabu 1-chome,